Cookies on the
LGC website
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on the LGC website. However, if you would like to, you can change your cookie settings at anytime.
Question markFind out more

LGC reports half year trading in line with expectations

04 Dec 2017
London, 8 November 2017 - Management confirms that trading is in line with expectations, with good momentum continuing through the second half of the year to 31 March 2018.

Key Highlights

Acquisition of LINK Technologies
LGC continued its expansion through targeted M&A, with the acquisition of LINK Technologies on 19 July 2017, strengthening its oligo reagents offering. LINK is a premier supplier of speciality reagents for oligonucleotide synthesis. Its products are used by oligonucleotide synthesis companies, university and commercial research departments as well as contract manufacturing organisations in the biotech sector.

Following the acquisition, LGC is combining its Biosearch oligonucleotide business, its Prime Synthesis Controlled Pore Glass business and LINK into the newly-formed Nucleic Acid Chemistry business, within its Genomics division.

Divestiture of the forensics division to Eurofins
On 16 October, LGC divested its forensics division to Eurofins Scientific (EUFI.PA), a European leader in Forensic DNA and Toxicology testing in France, Germany and Belgium.
LGC will continue to provide support to this business for a transitional period.
Tim Robinson, CEO LGC, said: “We are proud to have played a crucial role in the UK forensics landscape in the last two decades. During that time, LGC has invested significantly in improving the efficiency and effectiveness of delivering forensic evidence, with a very strong focus on quality and innovation. I am confident that the business is set for a successful and exciting future under the global reach and scientific expertise of Eurofins.”

LGC ranked 63 in The Sunday Times Grant Thornton Top Track 250
LGC is delighted to be ranked 63 (up from 109 in 2016) in The Sunday Times Grant Thornton Top Track 250 league table. LGC stands as the highest ranked life sciences company in the league table.

This achievement is recognition of LGC’s growth, including a 22% increase in sales from last year to top £300m and 19 acquisitions since 2011, seven of which came in the last year. LGC currently has more than 40,000 customers in over 150 countries.